



**Pfizer Inc**  
275 North Field Drive  
Lake Forest, IL 60045

October 18, 2019

### Supply Update Notification for Vincristine Sulfate Injection, USP Presentations

Dear Valued Customer,

We're reaching out to let you know we are expecting imminent deliveries of an important product, Vincristine Sulfate Injection, USP. Pfizer is committed to providing this important medication to patients and to providing supply availability information so customers can best develop plans to facilitate patient care.

Given the criticality of this product to patients, we will continue to prioritize Vincristine and are expediting shipments in the near term. We expect to fully meet market need for this product, with our next delivery expected in late October. Based on current forecasts, we believe our next deliveries will meet current patient needs throughout the rest of the year. We expect to fully recover on this product by January 2020.

Please reference this table for current availability details as of October 18, 2019.

NDC 11 digit (UoS)	Product Description	Next Delivery	Recovery
61703-0309-06	Vincristine Sulfate Injection, USP 1 mg/mL Single Dose ONCO-TAIN™ Glass Fliptop Vial	Late Oct. 2019	January 2020
61703-0309-16	Vincristine Sulfate Injection, USP 2 mg/2 mL (1 mg/mL) Single Dose ONCO-TAIN™ Glass Fliptop Vial	Late Oct. 2019	December 2019

Pfizer will notify you as new information becomes available.

To review the most up-to-date information on product availability, please download the Availability Report from our [pfizerinjectables.com](http://pfizerinjectables.com) website. Our Supply Continuity Team is a dedicated group that provides the latest information on product availability and customer order status. You can contact our Supply Continuity Team between 7:00am – 6:00pm CT at 1-844-646-4398 (select option 1 [Customer], then option 3 [Supply Continuity Team]).

Please reach out to your Pfizer Hospital sales representative or sales executive if you have any questions.

Thank you,

Chris Hernandez  
Portfolio Director, Oncology and Alternate Site

